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Abstract
Background—Repetitive transcranial magnetic stimulation (RTMS) targeting the left 
dorsolateral prefrontal cortex (DLPFC) is a treatment option for patients with medication-resistant 
major depressive disorder (MDD). However, antidepressant response is variable and there are 
currently no response predictors with sufficient accuracy for clinical use.
Objective—We report on results of an observational open-label study to determine whether the 
modulatory effect of 10 Hz motor cortex (MC) rTMS is predictive of the antidepressant effect of 
10 Hz DLPFC rTMS.
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Methods—Fifty-one medication-resistant MDD patients were enrolled for a 10-day treatment 
course of DLPFC rTMS and antidepressant response was assessed according to post-treatment 
reduction of the 17-item Hamilton Rating Scale for Depression score. Prior to treatment, we 
assessed the modulation of motor evoked potential (MEP) amplitude by MC rTMS. MEP’s were 
induced with single TMS pulses and measured using surface electromyography. MEP modulation 
was calculated as the change of mean MEP amplitude after MC rTMS.
Results—MEP modulation proved to be a robust predictor of reduction of clinician-rated 
depression severity following the course of DLPFC rTMS: larger MC rTMS-induced increase of 
corticospinal excitability anticipated a better antidepressant response. This was found both in 
univariate analyses (Spearman regression: rho=0.43, p<0.005) and a multivariable linear 
regression model (β=0.25, p<0.0001) controlling for baseline depression severity, age and resting 
motor threshold.
Conclusions—These findings suggest that MC rTMS-induced modulation of corticospinal 
excitability warrants further evaluation as a potential predictive biomarker of antidepressant 
response to left DLPFC 10 Hz rTMS.
Keywords
MDD; rTMS; dorsolateral prefrontal cortex; motor cortex; excitability; antidepressant response 
prediction
Introduction
Major depressive disorder (MDD) is a common disorder, frequently with a chronic and 
disabling course (1), and partial or non-response to first-line treatment options (2, 3). 
Transcranial magnetic stimulation (TMS), a technique based on electromagnetic induction, 
allows for focal non-invasive modulation of neural activity in discrete cortical regions (4). 
Repetitive TMS (rTMS) has therapeutic effects in MDD when applied at high frequencies 
(10 or 20Hz) to the left dorsolateral prefrontal cortex (DLPFC) (5–7), and is useful in 
patients with medication-resistant MDD (8). However, not all DLPFC rTMS candidates 
respond to treatment, with certain factors, such as age, medication resistance and episode 
duration (8–10), predicting poor antidepressant response, and others, such as psychomotor 
retardation and baseline sleep disturbance (9, 11), predicting enhanced response. 
Unfortunately, while these factors predict antidepressant response to rTMS at a group level, 
they are not sufficiently accurate to guide decisions regarding individual patients (e.g., 
patient selection).
Variability in antidepressant efficacy of rTMS also depends on treatment parameters, namely 
stimulation intensity (12) and stimulation site (13), raising the possibility of individualizing 
such parameters in order to optimize antidepressant response (12, 13). To this end, definition 
of rTMS-related biomarkers will be instrumental for accurate identification of patients in 
need of parameter adjustment (i.e., those who would otherwise not improve with DLPFC 
rTMS) and for correct definition of individual parameter adjustments (14). Intrinsic 
connectivity has been proposed as a biomarker for individualization of the stimulation target 
(15, 16), but strategies to optimize rTMS stimulation intensity are lacking. Currently, in an 
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attempt to balance treatment efficacy and safety, intensity is adjusted for each patient as a 
percentage of the resting motor threshold (RMT), i.e the minimum intensity needed to 
reliably produce an electromyographic (EMG) or movement response in a finger, when the 
contralateral motor cortex (MC) is stimulated (17). RMT-adjustment of stimulation intensity 
for safety purposes is unquestioned (17). However, the relationship of RMT with final 
antidepressant response is equivocal (10, 18), possibly because rTMS intensity is associated 
with antidepressant response (19), and absolute intensity is defined according to RMT. 
Finally, other biomarkers proposed for rTMS intensity adjustment, namely coil-to-cortex 
distance, an indirect measure of cerebral atrophy, were of limited success (20).
It is thought that the therapeutic antidepressant effects of rTMS are mediated by modulation 
of prefrontal cortex excitability (5, 21). However, measurements of the relationship between 
rTMS-induced modulation of cortical excitability and clinical response to DLPFC rTMS 
have not been performed. Such studies could provide novel biomarkers for patient selection 
and individualization of treatment parameters and, in addition, contribute towards a better 
understanding of the mechanisms underlying rTMS efficacy. Here we examined whether 
modulation of motor cortex excitability by rTMS, measured prior to DLPFC rTMS 
treatment, is predictive of antidepressant treatment efficacy. Excitability modulation of the 
motor cortex, rather than the prefrontal cortex, was tested because it can be readily assessed 
by measures of corticospinal excitability, such as the amplitude of TMS-induced motor 
evoked potentials (MEP) (22). We hypothesized that facilitatory modulation of corticospinal 
excitability would be related to an enhancement of antidepressant response.
Material and Methods
Subjects
To address our hypothesis, an observational open-label study was conducted in medication-
resistant outpatients, fulfilling DSM-IV criteria for the diagnosis of MDD, and who had 
failed at least three trials of adequate psychopharmacology treatment. Exclusion criteria 
were based on international safety guidelines for use of TMS (17). Participants were selected 
from 73 patients referred to the Berenson-Allen Center for Noninvasive Brain Stimulation 
for rTMS for treatment of MDD (Figure 1), 51 of who were eligible and consented to 
participate. In these participants, a stable antidepressant medication regimen was maintained 
4 weeks prior to the trial and throughout rTMS treatment. Five participants did not complete 
the rTMS treatment protocol and one had missing data regarding primary and secondary 
outcomes. The study was carried out in accordance with the Declaration of Helsinki and 
approved by the Beth Israel Deaconess Medical Center’s Internal Review Board. Informed 
consent for experimentation with human subjects was obtained from all subjects.
Clinical ratings and response classification
Severity of depression was assessed at baseline and after 2 weeks of rTMS treatment, with 
the clinician-rated 17-item Hamilton Rating Scale for Depression (HAM-D-17 (23, 24)), 
administered by a board-certified psychiatrist, and the self-report 21-item Beck Depression 
Inventory-II (BDI-II (25, 26)). Clinical response to rTMS was calculated as the percentage 
of score reduction after the second week of treatment, relative to baseline, on the HAM-
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D-17 
and BDI-II scores 
. Positive 
values reflect a decrease in HAM-D-17 or BDI-II scores after treatment, representing 
improvement in depression symptoms after rTMS, while negative values denote worsening 
of severity of symptoms. Exploratory analyses were conducted on the number of patients 
responding to treatment (responders), defined according to a reduction of symptom severity 
of at least 50% after 2 weeks of treatment, as measured by HAM-D-17 total scores.
TMS procedures
TMS was performed using a Magstim SuperRapid Stimulator (Magstim Company Ltd., UK) 
equipped with a commercially available 70-mm figure-of-eight coil. Sites for TMS were 
marked on a tightly fitting swimming cap placed on each patient’s head, to ensure accurate 
repositioning of the coil. For all procedures, the coil was held at approximately 45° to the 
midline and positioned tangentially to the skull with the handle pointing backward. Patients 
were seated in a comfortable chair with the elbow semi-flexed, and instructed to keep their 
hands as relaxed as possible. Resting motor threshold, established prior to all rTMS 
sessions, was defined using EMG techniques and according to international 
recommendations (27), as the lowest intensity of a single TMS pulse capable of eliciting at 
least 5 MEPs, with amplitude of at least 50 μV peak-to-peak, in a series of 10 consecutive 
single pulses delivered to the MC. Muscle activity was recorded with surface electrodes (Ag-
AgCl, 10 mm diameter) overlying the right abductor pollicis brevis (APB) muscle, and 
surface EMG signals were amplified (×1000), filtered (20–1000 Hz) and sampled at 2000 
Hz (PowerLab 4/25T, AD Instruments Ltd., Australia; Scope, version 4.0). The optimal 
scalp position over the MC to elicit maximal amplitude MEPs in the APB was identified 
(APB ‘hotspot’), and pulses were delivered with an inter-stimulus interval of at least 7s.
In an initial rTMS session (day 0), we assessed the modulation of MC excitability by rTMS 
(22), in accordance with methods previously applied by Maeda and colleagues to obtain 
mostly, but not exclusively, MEP facilitation in a sample of healthy individuals (28). For that 
purpose, MEPs were induced using single TMS pulses, delivered to the MC at an intensity 
of 120% of RMT, with a random stimulus interval of approximately 10 seconds (±1 second). 
Muscle relaxation was monitored through visual inspection of EMG signal, to ensure that 
single-pulses were delivered in the absence of active muscle contraction. MEP amplitude 
was measured peak-to-peak and averaged across 10 consecutive MEPs. Patients then 
received a single rTMS session over the APB ‘hotspot’ with the same parameters as those 
used for treatment: twenty 8-second long 10 Hz stimulation trains at 90% RMT intensity, 
with 52-second inter-train intervals (1600 stimuli). Approximately 30 s after completion of 
MC rTMS MEP amplitude was measured again, in the same manner as prior to rTMS. 
During both the MEP amplitude assessments and the delivery of MC rTMS, muscle 
relaxation was carefully monitored through visual inspection of hand and wrist muscle 
twitching, which was not found. An index of modulation of MC excitability was calculated 
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as the percentage change of mean MEP amplitude, post-rTMS relative to pre-rTMS 
, with positive values (MEP 
amplitude increase) reflecting facilitation of cortical excitability by rTMS, and negative 
values (MEP amplitude decrease) representing suppression (table 1). Both patients and the 
investigators administering therapeutic rTMS were kept blind to these results. The 
therapeutic rTMS protocol consisted of 10 daily sessions (delivered in 5 consecutive 
sessions per week over the DLPFC, defined as a site 5 cm anterior to the APB ‘hotspot’, in 
the same parasagittal plane. In each treatment session, rTMS was delivered as described for 
MC rTMS.
Statistical methods
Analyses were performed using SAS software (version 9.3, SAS Institute, Cary, North 
Carolina). Data for continuous measurements is presented as the mean ± standard deviation 
(SD). Assessment of normal distribution of continuous measurements was performed 
according to analysis of kurtosis, skewness and comparison of mean and median. Only % 
change of MEP amplitude was not normally distributed. For univariate analyses of binary 
predictors of clinical response (gender and handedness), outcome measures were compared 
between groups using unpaired t-tests. For continuous predictor variables, univariate 
analyses of correlation with outcome measures were conducted using Pearson r correlation 
coefficients (age, baseline depression severity scores and RMT) or Spearman rho correlation 
coefficients (for % change of MEP amplitude). Hierarchical multivariable linear regression 
models were used for adjusted analyses of the relationship between outcome variables and 
potential response predictors. Initial models for each outcome were based on prior 
knowledge, with age and baseline depression severity included as potential predictors of 
antidepressant response, and neurophysiologic variables of interest (% change of MEP 
amplitude and RMT) were then sequentially added to the initial models. Gender was 
included in model building of all models, but was neither a significant predictor nor a 
confounder, and thus was dropped. Data transformations and polynomial models were used 
to test the better alternative to fit continuous predictors, model assumptions were tested by 
analyses of residuals, and influence diagnostics were conducted using Cook’s distance. 
Exploratory receiver operating characteristic (ROC) analyses were performed using logistic 
regression, to determine the accuracy of % change of MEP amplitude to discriminate 
between responders and non-responders (as defined above). The area under the curve (AUC) 
was computed as a quantitative measure of test performance. All statistical tests were two-
tailed, with statistical significance defined at p < 0.05.
Results
In the original study sample, participants were 18 to 78 years old and 56.9% were women. 
The pre-treatment measurement of % change of MEP amplitude after MC rTMS was 
collected in all participants and was highly variable between individuals. Six patients were 
excluded from outcome analyses due to not completing the treatment protocol (n=5) or to 
missing data on both outcome measures (n=1). Of the 45 remaining patients, data were 
missing on the primary outcome in 4 and the secondary outcome in 1 (see Figure 1 for a full 
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description of experimental timeline). The primary and secondary outcomes were strongly 
correlated (r=0.69, p<0.001) suggesting that, as expected, they were expressions of a similar 
construct. Mean % reduction HAM-D-17 score (22.7%) and mean % reduction BDI-II score 
(18.2%) were moderate relative to other DLPFC rTMS studies (6, 7), as was the number of 
responders (n=7, 17.1%), possibly due to the relatively low stimulation intensity used here 
(19) and to the high refractoriness of MDD in these patients, who had failed at least three 
good trials of different antidepressants). A full description of the data collected for this study 
is given in Table 1 and Supplementary table 1.
In univariate analyses, the primary outcome measure (% reduction HAM-D-17) was found 
to correlate with the secondary outcome (% reduction BDI-17; r=0.69, p<0.001) and with 
baseline HAM-D-17 (r=−0.39, p<0.015). However, correlations with age, baseline RMT or 
baseline BDI-II were not significant (−0.4<r<-0.1, p>0.3), and % reduction HAM-D-17 also 
did not differ according to gender or handedness (t-tests, p>0.1; Table 1). Importantly, our 
main predictor of interest (% change MEP amplitude) correlated significantly both with the 
primary (rho=0.43, p<0.005; Figure 2) and secondary outcomes (rho=0.51, p<0.005, Figure 
2).
Hierarchical multiple linear regression models were then used for adjusted analyses of the 
relationship between the primary outcome and potential response predictors (Table 2). As 
expected, in the initial model (model 1, adjusted R2=0.18) baseline depression severity 
(HAM-D-17) was a significant predictor of worse antidepressant response, and age had a 
significant quadratic relationship with outcome, suggesting enhanced antidepressant 
responses in patients at the center of the age distribution. In a sequential model including 
also MEP amplitude change, this variable was found to be a very significant predictor of 
enhanced antidepressant response (β=0.21±0.06, p<0.001), more than doubling the 
predictive potential of the model (model 2, adjusted R2=0.39). This association was robust to 
inclusion of baseline RMT in a third exploratory model, where RMT was also a significant 
predictor of outcome (β=−0.7±0.3, p<0.05) and the predictive potential of the model was 
further enhanced (model 3, adjusted R2=0.48; Table 2). In additional multivariable models 
for prediction of the secondary outcome (BDI-II change), MEP amplitude change, but not 
age, baseline depression severity (BDI-II) and baseline RMT, was still a significant predictor 
of response (models 4 and 5; Table 2).
Data from several participants was excluded from multivariable modelling analysis for 
prediction of models 1 to 3. This was due to failure to complete rTMS treatment or absent 
depression severity assessments (HAM-D-17). Control analyses were thus conducted to 
compare demographic, neurophysiologic and clinical characteristics between these 
participants (n=10), and those who completed rTMS treatment and in whom both pre- and 
post-treatment HAM-D-17 assessments were available (n=41). No differences were found 
between the two groups regarding gender or handedness (Fisher’s exact test, p>0.2), nor 
regarding age, baseline depression severity (BDI-II), % reduction BDI-II, baseline RMT or 
% change MEP amplitude (t-tests, p>0.1; Supplementary table 1).
In this study, of the 41 patients completing DLPFC rTMS treatment and depression severity 
assessments (HAM-D-17) approximately 17% were responders to treatment, i.e., 
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experienced a reduction of symptom severity of at least 50%. This relatively low number of 
responders limits the utility of ROC analyses to determine the accuracy of MEP amplitude 
change to predict those that will be responders to rTMS. Nevertheless, an exploratory 
analysis was conducted, and the ROC curve of MEP amplitude change to identify 
responders to DLPFC rTMS was calculated. Interestingly, the area under the ROC curve was 
0.84, suggesting good to very good performance of MEP amplitude change in the prediction 
of response to DLPFC rTMS (i.e., 84% accuracy).
Discussion
Here we found that in individuals suffering from major depressive disorder, modulation of 
corticospinal excitability by rTMS delivered to the MC, measured prior to DLPFC rTMS 
treatment of depression, is correlated with antidepressant response to DLPFC rTMS (Table 
1, Figure 2). This finding was robust to measurement of antidepressant response using two 
different depression severity scales (HAM-D-17 and BDI-II; Table 1, Figure 2) and to 
adjustment according to demographic and clinical factors, in multivariable analyses (Table 
2). The mechanisms underlying interindividual variability in modulation of corticospinal 
excitability could be related to factors such as age (29), MDD severity (30–35) and coil-to-
MC distance (20, 36) (that correlates with RMT (36)). However, as shown in model 3 and 4, 
age, severity and RMT do not confound the relationship between modulation of 
corticospinal excitability and antidepressant response. Thus, these findings support our 
primary hypothesis, i.e., that the degree of modulation of corticospinal excitability by rTMS 
delivered to the left MC is predictive of the antidepressant effects of rTMS delivered to the 
left DLPFC.
These results are consistent with findings of altered cortical function in MDD, initially 
described using functional brain imaging and consisting mainly of reduced activity in 
prefrontal areas, particularly in the left hemisphere (37, 38). TMS has since been used as a 
tool for in vivo measurements of cortical excitability in several neuropsychiatric disorders, 
including MDD (39), with most studies specifically assessing MC excitability given the ease 
of measurement and interpretation of MC output, in terms of corticospinal excitability (21). 
Several authors have reported altered MC excitability in MDD (39), namely excitability 
differences between patients and controls, and/or interhemispheric asymmetry of excitability 
in patients, but not in controls (30–32). However, these findings have not been consistent 
across all studies (40, 41), possibly reflecting heterogeneity in the pathophysiology of MDD 
(42, 43) or confounding medication effects. Nevertheless, even though the motor cortex is 
not typically regarded as a critical brain area in the pathophysiology of MDD, altered MC 
excitability in depressed patients may represent more widespread pathological and 
neuroplastic changes due to altered of glutamatergic or GABAergic neurotransmission (44, 
45). The assay reported here allowed not only measurement of MC excitability but, 
critically, of corticospinal excitability modulation by rTMS. To our knowledge, such 
measures have not been systematically compared between depressed and control individuals 
in a single study. However, Maeda et al (28) used an identical method to the one used here in 
order to assess corticospinal excitability modulation by rTMS in healthy volunteers. 
Exploratory comparisons of the MEP facilitation obtained here in 51 depressed patients (8 
± 49%) and by Maeda et al in 14 healthy volunteers (37.9 ± 53.6%) reveal a borderline 
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significant difference between the two datasets (p=0.05; unpaired two-sample t-test). While 
this difference cannot be interpreted in the absence of a direct comparison in a single study, 
it suggests that, in the context of MDD, the MC may be less sensitive to the 
neuromodulatory effects of 10Hz rTMS. Future research should explicitly address this 
hypothesis, and it is important in this context to consider the potential effect of 
antidepressant and other medications that may have influenced this finding.
There is also evidence that corticospinal excitability is modified after effective 
antidepressant treatment with DLPFC rTMS (33–35), electroconvulsive therapy (46, 47) and 
vagus nerve stimulation (48), suggesting that it may be a modifiable state marker for the 
depressive state, rather than a trait marker for susceptibility to depression. Furthermore, 
antidepressant treatments such as rTMS, as well as ketamine, an experimental rapid-acting 
drug (5, 21), are thought to act through the modulation of synaptic function (49). Evidence 
for a direct association between antidepressant efficacy of these treatments and effects on 
synaptic function and neuroplasticity would thus provide critical added support for the 
relevance of such mechanisms in the context of depression pathophysiology and 
antidepressant affects. Prior studies attempting to identify measures of excitability to serve 
as biomarkers for antidepressant treatment with rTMS tested methods to assess excitability 
proper, such as RMT (10), MEP potential amplitude, cortical silent period and intracortical 
inhibition (18). This research had limited success (50) and, in positive studies, excitability 
was a weak and/or inconsistent predictor of antidepressant response (10, 18). Other 
approaches for assessment of cerebral activity, such as PET imaging (51) and 
electroencephalography (52), have also been used as predictive biomarkers of antidepressant 
response to rTMS, and corticospinal excitability has been tested as a predictor of response to 
other treatments, namely fluoxetine (53), sleep deprivation and light therapy (54), with only 
moderate success.
While prior studies had limited success in identification of rTMS treatment biomarkers, the 
research presented here is, to our knowledge, the first study to use measures of corticospinal 
excitability modulation by rTMS, rather than excitability proper. Importantly, we found that 
modulation of corticospinal excitability by rTMS delivered to the MC was a robust predictor 
of antidepressant response to DLPFC rTMS. In the most similar approach described in the 
available literature, magnetoencephalography was used to show that, relative to pre-
treatment, ketamine infusion increases excitability of the somatosensory cortex in response 
to tactile stimulation, specifically in patients with the most robust antidepressant responses 
(55). Use of such response predictors, reflecting individual modulation of motor or sensory 
reactivity in response to a proposed treatment course, in addition to contributing towards 
patient selection, could allow for diverse interventions to enhance treatment efficacy. One 
possibility would be to individualize rTMS treatment parameters, namely frequency, 
intensity (12, 20) and/or the stimulation paradigm proper (e.g., theta burst stimulation (56)), 
in order to identify the conditions that induce sufficient corticospinal excitability 
modulation. If, as proposed above, MDD patients are less sensitive to the neuromodulatory 
effects of MC rTMS than healthy subjects, another possibility would be to increase the 
likelihood of excitability modulation by rTMS, for example using concomitant interventions 
that may independently enhance cortical excitability, such as ketamine, caffeine or glucose 
(55, 57). Nevertheless, these proposals are speculative, and randomized trials will be 
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required to compare antidepressant outcomes between current standard rTMS treatment and 
individualized or enhanced treatment options. Furthermore, since antidepressant drugs in 
current clinical use have been shown to modify MC excitability after a single dose (58, 59), 
it is tempting to hypothesize that similar approaches, i.e., of treatment-induced changes of 
cortical excitability, could be useful for prediction of antidepressant response and/or 
adjustment of parameters (e.g., dosage), for treatments other than DLPFC rTMS.
The results of this study should be interpreted in the context of the experimental design. In 
fact, a relatively low number of MEPs was recorded before and after the MC rTMS session 
to assess modulation of corticospinal excitability (22), which could have increased 
variability due to a greater impact of outliers on the mean pre and post-treatment excitability. 
Nevertheless, since use of a higher number of MEPs has been shown to increase reliability 
of this measure (60), we expect that future research using such methodology will have a 
greater power to confirm the findings described here. The rTMS treatment protocol used was 
also atypical relative to those currently approved for clinical use, with only 10 and relatively 
short sessions of rTMS delivered at a low stimulation intensity (6, 7) to a DLPFC target that 
was not optimal (13), which could explain the low clinical response that was observed in 
these patients. Importantly, the parameters for DLPFC rTMS were chosen according to the 
parameters for MC rTMS, to enhance comparability between the neuromodulatory effects of 
the latter and the antidepressant effects of the former. However, rTMS effects may differ 
between the MC and the DLPFC (20, 36), which could limit interpretation of our findings. 
In any case, the protocol for MC rTMS was chosen to follow those previously reported for 
assessment of corticospinal excitability (28), including delivery of MC rTMS at a low 
intensity for safety concerns, and explaining, in part, the choice of atypical parameters for 
DLPFC rTMS. Finally, while the results described here have been interpreted as a reflection 
of the relevance of cortical excitability for rTMS treatment of depression, the contribution of 
spinal cord and peripheral nerve excitability towards the effects of MC rTMS, and/or the 
amplitude of MEPs, should be considered. To minimize this possibility, during TMS 
procedures participants were instructed to keep their hands relaxed. Muscle relaxation was 
carefully monitored through visual inspection of hand and wrist muscle twitching, which 
was not found. Thus, while contributions from non-cortical excitability are unlikely, they 
cannot be fully excluded. Follow-up studies should consider methods to address this 
problem, such as the use of concurrent TMS and electroencephalography (TMS-EEG) for 
direct cortical measurements (14), or assessment of the H-reflex to disentangle contributions 
from spinal excitability (61).
Conclusions
In conclusion, the findings reported here demonstrate that measures of motor cortex 
excitability modulation by rTMS predict antidepressant response to prefrontal cortex rTMS. 
Depending on further refinement of these measures, we propose they could be used for 
patient selection and optimization of rTMS parameters (20), in order to obtain an 
individualized level of modulation, and thus contribute towards optimization of rTMS 
treatment efficacy (14) and safety (17). While it is possible that measures of modulation of 
cortical excitability performed in the prefrontal cortex (62) could perform even better as 
predictors of response, this would require the use of concurrent TMS-EEG, which poses 
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additional technical and conceptual challenges (14). On the contrary, measures of 
corticospinal excitability, such as those used here, are well established, readily available in 
depressed patients under consideration for rTMS, and easier to interpret (21). Future 
research should confirm these findings in alternate rTMS centers and with other treatment 
parameters, and further explore details regarding how this approach can be used for patient 
selection and optimization of rTMS parameters.
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Highlights
• 10Hz rTMS of the dorsolateral prefrontal cortex (DLPFC) is used to treat 
depression.
• Motor evoked potential amplitude can be modified after 10Hz motor cortex 
(MC) rTMS.
• This index of excitability modulation predicts antidepressant response to 
DLPFC rTMS.
• rTMS-induced modulation of excitability is a potential antidepressant 
biomarker.
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Figure 1. 
Flowchart and timeline of experimental procedures.
Eligible patients were assessed for depression severity and motor cortex excitability, prior to 
10 daily sessions of DLPFC rTMS, performed over 2 weeks. After treatment, depression 
severity was assessed again, to measure clinical response.
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Figure 2. 
Relationship between modulation of corticospinal excitability by MC rTMS and 
antidepressant response to DLPFC rTMS.
Significant correlations were found between the percentage change of MEP amplitude after 
MC rTMS and the percentage reduction of depression severity after 10 days of DLPFC 
rTMS, measured both using the self-report Beck Depression Inventory-II (BDI; rho=0.51, 
p<0.005; panel A) and the clinician-rated Hamilton Rating Scale for Depression (HAM-D; 
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rho=0.43, p<0.005; panel B). The values for these correlations were similar when calculated 
using parametric analyses (r=0.55, p<0.0005 in both cases).
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